West Coast Sarcoma Conference 2024: Boehringer Ingelheim Roundtable
OR
Chair
Dr. Shantanu Banerji
Speakers
Dr. Jonathan Noujaim
Dr. Caroline Holloway
Dr. Hannah Abrams
Dr. Olga Vornicova
This program has been made possible through unrestricted support from Boehringer Ingelheim
Studies/trials discussed:
- Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
- STRASS II Study
